The Weight Loss Wars: A Battle of Numbers and Integrity The pharmaceutical industry is no stranger to exaggeration and misinformation, particularly when it comes to weight loss treatments.
A recent lawsuit between Novo Nordisk and Eli Lilly centers on dosage comparisons used in marketing materials for their respective products, Wegovy and Zepbound.
At issue are claims that Eli Lilly's advertisements are false and misleading by comparing peak doses of Zepbound against outdated, lower doses of Wegovy to advertise a 50 pound weight loss versus 33 pounds.